Effects of VEGF Inhibition

Inhibition of new and recurrent tumor vessel growth, as demonstrated in preclinical models

Targeting VEGF may result in ongoing inhibition of both new and recurrent tumor vessel growth (Table 1). It has been proposed that these effects may help inhibit tumor growth and metastasis.1-3

Research also suggests that blockade of VEGF signaling may help inhibit tumor growth by preventing new vessel growth at both primary and metastatic sites.4

Table 1. Proposed effects of VEGF inhibition1-11

Tumor vessel inhibition

Tumor vessel regression

Interferes with the ability of VEGF to help tumor vessels establish and grow

Associated with reduced tumor growth and decreased metastatic potential

Interferes with the ability of VEGF to help tumor vessels survive

Associated with reduction in microvascular density and tumor volume

Regression of existing tumor vasculature, as demonstrated in preclinical models

Based on preclinical models, it has also been proposed that VEGF inhibition may regress existing tumor vessels (Table 1). These reductions in microvascular density have been associated with a reduction in tumor volume and weight (Figure 1).3,5-8,12-15

Figure 1. Microcomputed tomography image showing effect of VEGF inhibition in a preclinical model8

Control tumor (no VEGF inhibition)

After 48 hours of VEGF inhibition


  1. Borgström P, Hillan KJ, Sriramarao P, Ferrara N. Cancer Res. 1996;56:4032-4039. PMID: 8752175
  2. Borgström P, Bourdon MA, Hillan KJ, et al. Prostate. 1998;35:1-10. PMID: 9537593
  3. Warren RS, Yuan H, Matli MR, et al. J Clin Invest. 1995;95:1789-1797. PMID: 7535799
  4. Ellis LM, Hicklin DJ. Nat Rev Cancer. 2008;8:579-591. PMID: 18596824
  5. Lee CG, Heijn M, di Tomaso E, et al. Cancer Res. 2000;60:5565-5570. PMID: 11034104
  6. Willett CG, Boucher Y, di Tomaso E, et al. Nat Med. 2004;10:145-147. PMID: 14745444
  7. Yuan F, Chen Y, Dellian M, et al. Proc Natl Acad Sci U S A. 1996;93:14765-14770. PMID: 8962129
  8. O’Connor JPB, Carano RAD, Clamp AR, et al. Clin Cancer Res. 2009;15:6674-6682. PMID: 19861458
  9. Jain RK. Nat Med. 2001;7:987-989. PMID: 11533692
  10. Jain RK. Science. 2005;307:58-62. PMID: 15637262
  11. Folkman J. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Vol 2. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:2865-2882.
  12. Tong RT, Boucher Y, Kozin SV, et al. Cancer Res. 2004;64:3731-3736. PMID: 15172975
  13. Tobelem G. VEGF: a key therapeutic target for the treatment of cancer—insights into its role and pharmacological inhibition. Targ Oncol. 2007;2:153-164.
  14. Dickson PV, Hamner JB, Sims TL, et al. Clin Cancer Res. 2007;13:3942-3950. PMID: 17606728
  15. Rowe DH, Huang J, Kayton ML, et al. J Pediatr Surg. 2000;35:30-32. PMID: 10646769